.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Johnson and Johnson
McKinsey
Teva
McKesson
US Army
Cerilliant
QuintilesIMS
Moodys
Colorcon

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,857,802

« Back to Dashboard

Which drugs does patent 7,857,802 protect, and when does it expire?


Patent 7,857,802 protects NAROPIN and is included in one NDA. There have been zero Paragraph IV challenges on Naropin  and

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 7,857,802

Title:Connector for medical liquid-containing packages and medical liquid-containing packages
Abstract: The invention relates to a connector for medical liquid-containing packages, in particular to infusion or transfusion bags comprising a connection element (1) provided with a channel-shaped opening (1c) in which a self-sealing membrane (8) is arranged. A breakable part (17) which is connected to the connection piece closes the channel-shaped opening. Above the membrane (8), said connection element is embodied in the form a connection piece (13) comprising an internal cone (14) and external thread (15), the membrane (8) being sealed for receiving a syringe cone shaft. The inventive connector makes it possible to inject an active substance by means of a conventional Luer lock syringe devoid of an injection cannula (needle).
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Rahimy; Ismael (Friedberg, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg V.D.H., DE)
Application Number:10/575,690
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Fresenius Kabi Usa
NAROPIN
ropivacaine hydrochloride
SOLUTION;INJECTION020533-006Sep 24, 1996APRXYesNo7,857,802► SubscribeY
Fresenius Kabi Usa
NAROPIN
ropivacaine hydrochloride
SOLUTION;INJECTION020533-007Sep 24, 1996RXYesNo7,857,802► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,857,802

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 48 016Oct 15, 2003
PCT Information
PCT FiledOctober 15, 2004PCT Application Number:PCT/EP2004/011603
PCT Publication Date:April 28, 2005PCT Publication Number: WO2005/037362

International Patent Family for Patent: 7,857,802

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
MexicoPA06004241► Subscribe
South Korea101160278► Subscribe
South Korea20070007248► Subscribe
Japan4684233► Subscribe
Japan2007508081► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
UBS
Colorcon
US Army
Moodys
Mallinckrodt
Dow
McKesson
US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot